Clinical trials: Solid Malignant Tumor
Advanced Solid Tumors
A Study of ASKG315 in Patients With Advanced Solid Tumors.
The study is a Phase 1, open-label, multicenter, dose escalation study to evaluate the safety, tolerability, PK and PD of ASKG315 as a single agent in patients with advanced solid tumors.
- Trial name
- NCT05554666
- Testing
- ASKG315
- Where
- 4 sites in China
- Volunteers
- 56 people
- Sponsor
- AskGene Pharma, Inc.
Advanced Solid Tumor
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
This is a phase 1 study designed to evaluate the safety, tolerability, and antitumor activity of FT825 (also known as ONO-8250) with or without monoclonal antibody therapy following chemotherapy in participants with advanced…
- Trial name
- NCT06241456
- Testing
- FT825, Fludarabine, Cyclophosphamide
- Where
- 14 sites in United States
- Volunteers
- 351 people
- Sponsor
- Fate Therapeutics
Advanced Solid Tumors
A Phase I/II Study to Evaluate XNW34017 in Patients With Advanced or Metastatic Solid Tumor
This study is an open-label, dose-escalation, multicenter Phase I/II study conducted in patients with advanced solid tumors. The target population for this study consists of patients with advanced solid tumors who have failed or…
- Trial name
- NCT07327294
- Testing
- XNW34017
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Evopoint Biosciences Inc.
Advanced Solid Tumor, Lymphoma
Open-label Study of DS-8273a to Assess Its Safety and Tolerability, and Assess Its Pharmacokinetic and Pharmacodynamic Properties in Subjects With Advanced Solid Tumors or Lymphomas
This will be a Phase 1, open-label study of DS-8273a to assess its safety and tolerability, identify the Maximum Tolerated Dose and/or Maximum Administered Dose, and assess its properties in subjects with advanced solid tumors or…
- Trial name
- NCT02076451
- Testing
- DS-8273a
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Daiichi Sankyo
Solid Tumor
Study of Cobimetinib in Participants With Solid Tumors
This non-randomized, open-label, study will determine the highest safe dose of cobimetinib, how often it should be taken, how well participants with cancer tolerate cobimetinib and will assess the pharmacokinetic effect of…
- Trial name
- NCT00467779
- Testing
- cobimetinib, dextromethorphan, midazolam
- Where
- 4 sites in United States
- Volunteers
- 119 people
- Sponsor
- Genentech, Inc.
Advanced Solid Malignancies
A Phase I Study of MEDI9447 (Oleclumab) in Japanese Patients
This is a phase I, open-label study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of MEDI9447 in Japanese patients with advanced solid malignancies.This study consists of 2 cohorts.
- Trial name
- NCT03736473
- Testing
- MEDI9447 (oleclumab)
- Where
- Japan
- Volunteers
- 6 people
- Sponsor
- AstraZeneca
Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer
MGC018 With or Without MGA012 in Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of vobramitamab duocarmazine (MGC018) in patients with advanced solid tumors.
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer, Melanoma, Advanced Solid Tumor, Adult
- Trial name
- NCT03729596
- Testing
- vobramitamab duocarmazine
- Where
- 21 sites in United States, Australia and 2 more
- Volunteers
- 143 people
- Sponsor
- MacroGenics
Diffuse Large B Cell Lymphoma, Primary Mediastinal Lymphoma
Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients
This is a Phase 1, open-label, two-part, safety, PK, and activity study designed to characterize the DDI potential of tazemetostat. Tazemetostat will be taken orally BID continuously in 28-day cycles in both study parts.
- Conditions
- Diffuse Large B Cell Lymphoma, Primary Mediastinal Lymphoma, Mantle Cell Lymphoma, Advanced Solid Tumor
- Trial name
- NCT03028103
- Testing
- Tazemetostat, Fluconazole, Omeprazole
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Epizyme, Inc.
Neoplasms
A Phase II Study of Carboplatin Plus Irinotecan Versus Irinotecan in Children With Refractory Solid Tumors
This clinical research study is being conducted to investigate the effectiveness of combining carboplatin and irinotecan, versus irinotecan alone, in treating children who have refractory solid tumors.
- Trial name
- NCT00057473
- Testing
- carboplatin + irinotecan, irinotecan
- Where
- 2 sites in United States
- Sponsor
- Bristol-Myers Squibb
Cancer, Solid Tumor
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
This is a multiphase, multicenter study, which includes a Phase 1a open-label, dose escalation monotherapy study of ST-067 given as an SC injection with or without obinutuzumab [Gazyva®] pre-treatment, by IV infusion, and in…
- Conditions
- Cancer, Solid Tumor, Melanoma, Renal Cell Carcinoma
- Trial name
- NCT04787042
- Testing
- ST-067, Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA], pembrolizumab
- Where
- 6 sites in United States
- Volunteers
- 316 people
- Sponsor
- Simcha IL-18, Inc.
Advanced Solid Tumor
This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors
This is a first-in-human Phase 1, single-arm, open-label, multicenter, multiple-dose, dose-escalation and dose-expansion study of ABL503 to evaluate the safety, tolerability, MTD and/or RP2D, PK, immunogenicity, preliminary…
- Trial name
- NCT04762641
- Testing
- ABL503
- Where
- 8 sites in United States, South Korea
- Volunteers
- 100 people
- Sponsor
- ABL Bio, Inc.
Solid Tumor
Study of MK-4166 and MK-4166 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4166-001)
This is planned to be a 5-part dose-escalation study to determine the safety and tolerability of MK-4166 monotherapy and MK-4166 plus pembrolizumab combination therapy, and to establish the maximum tolerated dose (MTD) or maximum…
- Trial name
- NCT02132754
- Testing
- MK-4166, Pembrolizumab
- Volunteers
- 116 people
- Sponsor
- Merck Sharp & Dohme LLC
Solid Tumor
A Clinical Study Evaluating the Safety and Efficacy of BioTTT001 in Patients With Malignant Solid Tumors
This is a Phase 1 open-label study to evaluate the safety, tolerability, and pharmacokinetics of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) at dose of 5×10∧9VP、5×10∧10VP、5×10∧11VP in Patients With…
- Trial name
- NCT06215846
- Testing
- BioTTT001 injection
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Beijing Bio-Targeting Therapeutics Technology Co., Ltd
Advanced Solid Tumor, BRAF Gene Mutation
Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations
This BVD-523-ABC study builds on the safety and clinical activity experience of previous studies that have evaluated ulixertinib as a novel targeted cancer treatment in cohorts of patients with specific genetic alterations and…
- Conditions
- Advanced Solid Tumor, BRAF Gene Mutation, BRAF Gene Alteration, MEK Mutation
- Trial name
- NCT04488003
- Testing
- Ulixertinib, Physician's Choice
- Where
- 22 sites in United States
- Volunteers
- 104 people
- Sponsor
- BioMed Valley Discoveries, Inc
Solid Tumors
Phase Ia/Ib Study of RS-0139 in Patients With a Recurrent, Locally Advanced or Metastatic Solid Tumors
This study designed as a multicenter, open label, two-step study to determine the optimum dose, pharmacokinetics, and the safety of RS-0139 in patients with a recurrent, locally advanced or metastatic solid tumors.
- Trial name
- NCT04261413
- Testing
- RS-0139
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 16 people
- Sponsor
- RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S.
Solid Tumor, Adult
A Study of HB0045 Injection in Patients With Advanced Solid Tumors
This is a phase I/II, open-label, multicenter study . During the study, subjects will be evaluated for safety, toxicity, tolerability, PK/PD, immunogenicity, biomarkers, and antitumor activity of HB0045.
- Trial name
- NCT06056323
- Testing
- HB0045 Drug Product
- Where
- 3 sites in United States
- Volunteers
- 71 people
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
Advanced Malignant Solid Tumors
A Phase I Clinical Study of AK150 in Advanced Malignant Solid Tumor
This study is an open-label, multicenter, dose-escalation and dose-expansion Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of AK150…
- Trial name
- NCT07566247
- Testing
- AK150
- Where
- 3 sites in China
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Akeso
Advanced Solid Tumors Cancer
A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)
This is an open-label, Phase I, dose-escalation study to determine the maximum tolerated dose (MTD) and the recommended phase two dose (RPTD), and to assess the safety, preliminary efficacy, and pharmacokinetic (PK) profile of…
- Trial name
- NCT03145909
- Testing
- ABBV-176
- Where
- 11 sites in United States, Australia and 2 more
- Volunteers
- 19 people
- Sponsor
- AbbVie
Solid Tumor
Study of ZGGS34 in Participants With Advanced Solid Tumors
This is a multicenter, open-label Phase 1/2 study in participants with advanced solid tumors. The study consists of two parts: Part 1 is a dose-escalation phase to evaluate the safety and tolerability of ZGGS34 in advanced solid…
- Trial name
- NCT07258121
- Testing
- ZG006
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Advanced Solid Malignancies, Malignant Lymphoma
Global Phase1 Study to Assess the Safety and Tolerability of AZD1208 in Advanced Solid Tumors and Malignant Lymphoma
The purpose of this study is to investigate the safety and tolerability of AZD 1208 up to a maximum tolerated dose (MTD) and define the dose(s) for further clinical evaluation when given daily to patients with advanced solid…
- Trial name
- NCT01588548
- Testing
- AZD1208
- Where
- 3 sites in Japan, United Kingdom
- Volunteers
- 43 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.